EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke

Khanh Nguyen Duy, Diem Thi Nguyen, Minh Van Le, Long Duy Le, Huy Cong Tran, Nhan Huu Kha, An Viet Tran, Bao Lam Thai Tran

Trends in Medical Sciences · 2022

DOI: 10.5812/tms-122415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Medical Sciences, 2022. Verfasst von Khanh Nguyen Duy und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Deep vein thrombosis (DVT) is a severe complication in patients with acute ischemic stroke. It can cause severe pulmonary embolism, which may result in death. DVT prevalence in ischemic stroke patients ranges from 20 to 70%. Enoxaparin in prophylactic treatment can decrease the risk of developing DVT in patients with acute ischemic stroke. However, optimal enoxaparin dosing for prophylactic treatment in DVT remains elusive. Dosing between 0.3 - 0.5 IU/mL could decrease the prevalence of DVT without increased complications.

Objectives

This study aims to evaluate the benefits and risks of prophylactic treatment in DVT patients with dosing of enoxaparin (Lovenox of Sanofi-Aventis Vietnam Company) 40 mg (4,000 units of anti-Xa, 0.4 mL) once daily.

Methods

Following a cross-sectional design, 58 patients with acute ischemic stroke, who met the inclusion criteria, were studied. Participants received prophylactic treatment of the lower extremities DVT with enoxaparin.

Results

The mean Wells score was 2.14 ± 0.35. Based on the Wells criteria for DVT, all cases had paralysis, muscle weakness, and bedridden recently > 3 days. Also, 4 cases (6.9%) had leg edema; 1 case (1.7%) had superficial collateral veins; 3 cases (5.3%) had previously documented DVT. Thrombocytopenia > 50% after treatment has a non-statistically significant decrease. The 2nd ultrasound showed no case of DVT.

Conclusions

Enoxaparin was not the primary cause of thrombocytopenia in prophylactic treatment. Enoxaparin is a 100% effective means to prevent lower extremity DVT in average-risk patients, and it does not increase the risk of bleeding.

Zitieren

APA

Duy, K. N., Nguyen, D. T., Le, M. V., Le, L. D., Tran, H. C., Kha, N. H., Tran, A. V., & Tran, B. L. T. (2022). Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke. Trends in Medical Sciences. https://doi.org/10.5812/tms-122415

Vancouver

Duy KN, Nguyen DT, Le MV, Le LD, Tran HC, Kha NH, et al. Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke. Trends in Medical Sciences. 2022. doi:10.5812/tms-122415

BibTeX
@article{Duy2022,
  author = {Duy, Khanh Nguyen and Nguyen, Diem Thi and Le, Minh Van and Le, Long Duy and Tran, Huy Cong and Kha, Nhan Huu and Tran, An Viet and Tran, Bao Lam Thai},
  title = {Enoxaparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke},
  journal = {Trends in Medical Sciences},
  year = {2022},
  doi = {10.5812/tms-122415}
}
Kostenlos starten →